But not in the clinic, albeit still a small sample for the Celgene drug. Results last month at EHA for their Phase I showed an ORR of just under 50% vs. just under 90% for ibrutinib in a roughly comparable population of R/R CLL. My guess is they focus on combo therapy, assuming they even move forward at all given how far behind it is.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.